1.01 USD
▼-0.06-5.61%
盘后 1.05 +3.96%
2026-11-20
市值
$6.65M
市盈率
—
EPS
-3.18
股息率
—
52 周区间
0.97 – 13.42
成交量
38.71K
Beta
1.24
目标价
17.67
52W 低 0.9752W 高 13.42
价格走势
公司简介
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece...